Regeneron Pharmaceuticals
Stock Forecast, Prediction & Price Target
Regeneron Pharmaceuticals Financial Estimates
Regeneron Pharmaceuticals Revenue Estimates
Regeneron Pharmaceuticals EBITDA Estimates
Regeneron Pharmaceuticals Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $16.07B N/A | $12.17B -24.25% | $13.11B 7.75% | Avg: $14.93B Low: $13.91B High: $15.57B avg. 13.87% | Avg: $16.03B Low: $15.14B High: $17.03B avg. 7.37% | Avg: $17.24B Low: $16.27B High: $18.31B avg. 7.52% | Avg: $18.33B Low: $17.31B High: $19.47B avg. 6.33% |
Net Income
% change YoY
| $8.07B N/A | $4.33B -46.27% | $3.95B -8.86% | Avg: $4.45B Low: $3.58B High: $5.12B avg. 12.79% | Avg: $5.21B Low: $4.37B High: $6.96B avg. 17.02% | Avg: $6.68B Low: $6.19B High: $7.22B avg. 28.07% | Avg: $7.28B Low: $6.75B High: $7.87B avg. 8.96% |
EBITDA
% change YoY
| $9.38B N/A | $5.17B -44.86% | $4.69B -9.27% | Avg: $6.38B Low: $5.94B High: $6.65B avg. 35.96% | Avg: $6.85B Low: $6.46B High: $7.27B avg. 7.37% | Avg: $7.36B Low: $6.95B High: $7.82B avg. 7.52% | Avg: $7.83B Low: $7.39B High: $8.32B avg. 6.33% |
EPS
% change YoY
| $76.4 N/A | $40.51 -46.97% | $37.05 -8.54% | Avg: $37.85 Low: $31.57 High: $45.07 avg. 2.14% | Avg: $45.39 Low: $38.51 High: $61.22 avg. 19.94% | Avg: $58.78 Low: $54.5 High: $63.53 avg. 29.49% | Avg: $64.05 Low: $59.38 High: $69.23 avg. 8.96% |
Operating Expenses
% change YoY
| $4.68B N/A | $5.61B 19.86% | $7.25B 29.11% | Avg: $2.62B Low: $2.44B High: $2.74B avg. -63.77% | Avg: $2.82B Low: $2.66B High: $2.99B avg. 7.37% | Avg: $3.03B Low: $2.86B High: $3.22B avg. 7.52% | Avg: $3.22B Low: $3.04B High: $3.42B avg. 6.33% |
FAQ
What is Regeneron Pharmaceuticals stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 16.71% in 2025-2028.
We have gathered data from 16 analysts. Their low estimate is 3.58B, average is 4.45B and high is 5.12B.
What is Regeneron Pharmaceuticals stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 8.77% in 2025-2028.
We have gathered data from 20 analysts. Their low revenue estimate is $13.91B, average is $14.93B and high is $15.57B.
What is Regeneron Pharmaceuticals stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 15.13% in 2025-2028.
We have gathered data from 16 analysts. Their low earnings per share estimate is $31.57, average is $37.85 and high is $45.06.
What is the best performing analyst?
In the last twelve months analysts have been covering Regeneron Pharmaceuticals stock. The most successful analyst is Evan David Seigerman whose win rate is 25%. He has correctly predicted 1/4 price targets.